in vivo-jetPEI™ transfection reagent for nucleic acid delivery is now available manufactured in full compliance with Good Manufacturing Practice (GMP), as required for clinical trials. A Drug Master File (DMF) describing the production of in vivo-jetPEI™ has been filed with the FDA, thus simplifying the documentation required for clinical trial applications. in vivo-jetPEI™ thus offers the possibility of using the same nucleic acid delivery reagent from early stages of preclinical research in animal models to clinical trials in humans.
|
